Chapter 2: RB1 mutation spectrum 25 2 2 26 Chapter 2: RB1 mutation spectrum abstRact background Retinoblastoma (Rb) is a childhood cancer of the retina, commonly initiated by biallelic inactivation of the RB1 gene. Knowledge of the presence of a heritable RB1 mutation can help in risk management and reproductive decision making. We report here on RB1 mutation scanning in a unique nation-wide cohort of Rb patients from the Netherlands.
IntRoductIon:
Retinoblastoma (Rb) is the most common intraocular malignancy in children and is almost always initiated by biallelic inactivation of the RB1 gene.
1-3 Some Rb patients (40%) have a heritable predisposition, caused by either an inherited familial RB1 mutation (familial heritable Rb) or a de novo germline RB1 mutation (sporadic or non-familial heritable Rb). Inactivation of the second RB1 allele in RB1 mutation carriers occurs in developing retinal precursor cells, either by mutation, loss of the wild type allele (with loss of heterozygosity (LOH) as a consequence), or promoter hypermethylation. RB1 mutation carriers can transmit the RB1 mutation in an autosomal dominant manner. The majority of RB1 mutation carriers develop bilateral Rb at a relatively early age, with an average age at diagnosis of 12 months. In addition to a predisposition for the development of Rb, germline RB1 mutation carriers have an increased risk for the development of second primary tumours.
4-6 Non-familial non-heritable Rb is usually caused by two somatic RB1 inactivating mutations in developing retinal cells, these patients are unilaterally affected (60% of all cases).
7
Children at increased risk for Rb are subjected to regular ophthalmological examination from birth until the age of four years, performed under a general anaesthetic from the age of three months. These eye exams would no longer be necessary if an increased risk could be excluded through DNA testing. Furthermore, knowledge of the presence of an RB1 mutation in the germline, or two RB1 mutations in the Rb tumour and none in the germline, can aid families in reproductive decision making 8 9 , emphasising the clinical importance for RB1 mutation scanning. The RB1 gene contains 27 exons, encoding the 928 amino acid long Rb protein (pRb). The Rb protein belongs to the family of pocket proteins, together with p107 (RBL1) and p130 (RBL2), which regulate the cell cycle by binding to E2F transcription factors.
10- 12 Since the discovery of the RB1 gene, a broad spectrum of germline and somatic RB1 mutations have been described, and can be accessed through many articles [13] [14] [15] [16] [17] , and the online Leiden Open Variation Database (LOVD), which includes over 1000 different RB1 mutations reported worldwide.
18
The majority of RB1 mutations are scattered throughout the gene, although several recurrent mutations and mutation hotspots exist.
15 17 19 We describe the distribution of RB1 mutations in a comprehensive national cohort, including more than 500 Dutch Rb patients from the Dutch Retinoblastoma Register. More than 180 RB1 germline mutations were detected including 33 novel mutations.
scanning of RB1 mutations in dna from peripheral blood lymphocytes Between 1990 and 1998 mutation detection in blood was first performed by means of Southern blotting, after which it was replaced by Single Strand Conformation Polymorphism analysis (SSCP). From 1998 until 2011, DNA analysis included direct sequencing of exons 1 and 15, as well as the RB1 promoter and Denaturing Gradient Gel Electrophoresis (DGGE) analysis of the other exons and flanking intronic sequences. To detect large deletions and duplications, Multiplex Ligation-dependent Probe Amplification (MLPA) analysis was performed using SALSA MLPA kit p047 RB1 (MRC-Holland, Amsterdam, the Netherlands). As of 2011, direct sequencing of all exons and the promoter, using in-house derived primers, was used instead of DGGE. In cases where no mutation was detected by Southern blotting and/or SSCP, mutation analysis was later repeated by DGGE, MLPA and/or sequencing, in so far as DNA was available. When novel putative splice mutations were detected (>2 nucleotides from intron exon boundary) and RNA was available, cDNA was studied to detect aberrant splicing. If warranted, e.g. when dysmorphic features or mental retardation was noted, karyotyping was performed in blood lymphocytes to detect chromosomal rearrangements.
When an RB1 mutation was found, DNA of the parents (if still alive) was tested for the mutation.
scanning of RB1 mutations in tumour dna
Since 2007 all non-familial unilateral cases in whom the eye was enucleated (n=34) were first tested for the RB1 mutations in tumour material and then DNA from blood was tested for the tumour mutations (n=34). For 19 non-familial unilateral cases diagnosed prior to 2007, tumour DNA was available and therefore these tumours were also tested. In addition, tumour DNA was tested of two out of 14 non-familial bilaterally affected patients in whom regular scanning of blood DNA did not detect a mutation. In addition to DGGE and/or sequencing analysis, as in analysis of DNA from blood, hypermethylation of the promoter was analysed by MLPA using MRC-Holland kit ME002-C1. LOH was investigated by two intragenic microsatellite markers (Rbi. 2 and RB1.20) . If these methods did not detect two mutations, MLPA of the tumour DNA was performed with the SALSA MLPA kit p047 RB1 (MRC-Holland, Amsterdam, the Netherlands) to detect large deletions and duplications.
additional mutation scanning Additional mutation scanning was performed for several cases with non-familial bilateral or familial Rb without a detectable RB1 mutation using regular scanning techniques. Lymphoblast cell lines were made of peripheral blood lymphocytes from two patients with non-familial bilateral Rb and three patients with familial Rb, RNA was extracted from cell lines and cDNA was analysed to detect possible deep intronic mutations that can lead to mis-splicing. The coding regions of RB1, RBL1 and RBL2 were covered by RT-PCR and analysed by electrophoresis (RB1, RBL1 and RBL2) and sequencing (RBL2). In addition an extended region of the promoter (-2500 to +700) was sequenced in blood DNA of four patients with familial Rb and nine patients with non-familial bilateral Rb to reveal possible promoter mutations that might alter the expression of RB1. See supplementary information for detailed methods.
Incomplete penetrance mutations
Mutations were regarded as incomplete penetrance mutations, when the diseased eye ratio (DER) in the family was ≤1.5, defined as the total number of affected eyes per family divided by the number of mutation carriers in the family. 21 To exclude possible mosaicism as a cause of milder expression, the oldest mutation carrier in these families was excluded from the analysis. statistics To determine differences in the frequencies of observed mutation types (nonsense, missense, splice and promoter) in our cohort and worldwide reported mutation frequencies from a meta-analysis by Valverde et al. 15 , the Chi-square goodnessof-fit test was performed. To determine differences in the distribution of RB1 mutations over the different exons and adjacent introns between familial, nonfamilial bilateral and non-familial unilateral patients, cross tables were analysed with the Fisher's exact test. P-values of <0.05 were considered significant.
Results
As of January 2013, 1173 patients were included in the Dutch Retinoblastoma Register. In Figure 1a the number of patients according to year of birth and the number of those patients scanned for RB1 mutations is depicted. From 1992, almost all newly diagnosed patients were tested at diagnosis, many patients diagnosed before 1992 were tested in retrospect. Figure 1b shows the inclusion of patients and the distribution of the mutations according to non-familial or familial cases and laterality. A total of 529 patients treated for Rb, 20 nonpenetrant RB1 mutation carriers, and two RB1 mutation carriers with retinoma, were included in our study. Fifty-two per cent of the Rb patients were male. Of these 529 Rb cases, 307 (58%) patients were unilaterally affected and 222 (42%) were bilaterally affected. The total of 529 Rb patients concerned 382 isolated non-familial cases and 147 familial cases belonging to 51 unrelated families, making the total of included unrelated families 433. An RB1 mutation in blood was detected in 187 (43%) out of these 433 unrelated families. The mutation detection rate for all bilaterally affected and/or familial cases was 92%, while of all nonfamilial unilaterally affected patients 10% turned out to have a germline RB1 mutation. Mutations were distributed across the entire gene and the promoter, excluding exons 5, 26 and 27 ( Figure 2) . Distribution per exon/intron was in accordance with previous studies.
15 17 We did detect a difference in the frequency of mutations over the different exons when we compared RB1 mutations in familial, non-familial bilateral and non-familial unilateral patients (Fisher's exact test, p-value 0.02). Figure 3 and table 1 show the frequency and percentages of the different types of mutations found, for all cases (Figure 3a) and separately for familial and nonfamilial cases (Figure 3b) . We compared the frequency of the type of mutation (nonsense, missense, splice and frameshift, excluding promoter mutations, large indels, and chromosomal deletions) with worldwide frequencies from a metaanalysis by Valverde et al. 15 describing 925 published RB1 mutations, belonging to Rb patients from 21 countries. No significant differences in the frequency of the type of mutation between our Dutch cohort and the worldwide frequencies were detected (p = 0.29) (Figure 3c ). 1 9 0 0 -1 9 0 9 1 9 1 0 -1 9 1 9 1 9 2 0 -1 9 2 9 1 9 3 0 -1 9 3 9 1 9 4 0 -1 9 4 9 1 9 5 0 -1 9 5 9 1 9 6 0 -1 9 6 9 1 9 7 0 -1 9 7 9 1 9 8 0 -1 9 8 9 1 9 9 0 -1 9 9 9 2 0 0 0 -2 0 0 9 2 0 1 0 novel and recurrent mutations A total of 144 different germline RB1 mutations were detected in 140 non-familial Rb cases and 47 Rb families, with 125 unique mutations occurring in only one Rb patient or Rb family of our cohort and 19 mutations occurring in two or more patients/ Rb families, which we defined as recurrent (supplementary table  8 ). Seventeen of the recurrent mutations were reported in the LOVD database 18 , including nine of the 11 well-known recurrent RB1 CGA>TGA nonsense mutations 13 22 23 , two of the recurrent mutations were not previously described (c.862-5T>G and c.1398del/ p.Glu466Aspfs*12). The 144 RB1 mutations detected in our cohort included 33 novel mutations, determined as mutations not previously detected in Rb according to the LOVD database.
18 These mutations are summarized in supplementary table 9. In supplementary tables 10 and 11 the germline mutations detected in our cohort in the RB1 gene that were not summarized in supplementary tables 8 and 9 are listed (not published). 15 , only nonsense, frameshift, splice site and missense mutations are included.
chromosomal deletions
In fourteen patients a de novo large microscopic deletion involving chromosome 13q band 14.2 was detected by karyotyping of peripheral blood lymphocytes (4% of non-familial patients). Figure 4 shows the different cytogenetically visible chromosomal anomalies. In two cases the 13q-deletion was only seen in respectively 9% and 10% of peripheral blood lymphocytes. Seven patients with a microscopic deletion were unilaterally affected and seven were bilaterally affected. All patients had developmental delay, ranging from mild to severe mental retardation.
non-pathogenic mutations
We detected two variants in RB1 that were previously described as diseasecausing in Rb, but additional evidence showed that these variants are more likely to be neutral variants. Nichols at al. 24 described the synonymous mutation c.42C>T, p.= in blood of a bilateral non-familial Rb patient, Hogg et al. 25 detected the same variant in a unilateral Rb tumour. We detected the variant in blood of two (unrelated) nonfamilial bilateral patients along with established pathogenic nonsense mutations in RB1, while both patients had healthy family members carrying the c.42C>T, p.= variant, including the father of one of the patients who had the variant in homozygous state. The variant c.1966C>T, p.Arg656Trp has been described as missense germline RB1 mutation by Nichols et al. 24 and Richter et al. 26 . The variant was detected by our laboratory in the germline of two non-familial unilateral patients and seven of their unaffected family members. The c.1966C>T, p.Arg656Trp variant was detected in the germline of a non-familial bilaterally affected patient in Germany as well. The patient also carried a deletion of exon [25] [26] 
Familial Rb
Our cohort included 147 familial Rb patients belonging to 51 families. In 47 families an RB1 mutation was detected. In four families consisting of an affected parent with affected children, RB1 mutation analysis did not detect a germline mutation. Of all familial cases 50 (34%) were diagnosed with unilateral Rb and 97 (66%) with bilateral Rb. In eleven families with Rb, one or more family members carried an RB1 mutation but were either unaffected or had a benign retinoma. Incomplete penetrance mutations were found in six three generation families with non-penetrant RB1 mutation carriers, as shown in Figure 5 . The mutations were three splice site mutations, two missense mutations and small deletion leading to a frameshift in exon 1. Pathogenicity of the splice site mutation c.862-5T>G mutation was confirmed by cDNA studies, showing a transcript missing exon 9. The c.862-5T>G mutation was confirmed in an Rb tumour from one of the c.862-5T>G carriers with the second hit being a nonsense mutation: c.1918A>T/ p.Lys640*. Pathogenicity of the splice site mutation c.2520+6T>C was confirmed by cDNA studies, showing a transcript missing exon 24. The mutation of family 5 (c.1970T>C/p.Leu657Pro) was not described previously as incomplete penetrance mutation. The other three mutations were previously described as RB1 mutations with incomplete penetrance.
27-29 Family 6 was previously described by Scheffer et al 30 . As depicted in the family trees, three family members without Rb who carried an RB1 mutation developed a potentially RB1-related tumour. Three non-familial Rb patients with an RB1 mutation (one with bilateral Rb and two with unilateral Rb) had an unaffected parent who turned out to be a carrier. Two of these mutations are known to be mutations with incomplete penetrance: c.862-5T>G (this paper); c.1981C>T (p.Arg661Trp). 28 The third mutation was a deletion of the complete RB1 allele. 29 Karyotyping and FISH analysis (LSI RB1) of skin fibroblasts showed the carrier parent to be mosaic for the deletion in 94% of metaphase cells. A remarkable observation was that an unaffected carrier of the c.2268T>A / p.Tyr756* nonsense mutation had three children and four grandchildren, all affected with bilateral Rb. Regular testing of blood lymphocytes did not show the (grand)mother to be mosaic. Lastly, a carrier of the nonsense mutation c.1333C>T / p.Arg445*, detected in her bilaterally affected child, did not develop Rb, but had a retinoma on fundus examination. Seven parents with Rb -six unilaterally affected and one with bilateral Rb-were unaware of the hereditary nature of their disease until the moment their child was diagnosed with Rb. Five of these children were born after 1992 and DNA testing would have been possible, had the parent been referred for RB1 testing. In ten patients with non-familial bilateral Rb and four families with familial Rb no RB1 mutation could be detected by standard RB1 DNA diagnostic analysis. Several of these patients were examined using additional methods to reveal possible deep intronic RB1 mutations, RB1 promoter mutations not investigated with standard mutation diagnostics or mutations in the RB1 family members RBL1 (p107) and RBL2 (p130). Although several (known) SNPs were detected, these additional methods did not reveal evidence for pathogenic mutations in RB1, RBL1 and RBL2 (See supplementary results).
non-familial Rb
A germline RB1 mutation was detected in 140 out of 382 non-familial Rb patients. In 25 out of 257 non-familial unilaterally affected cases a mutation was detected (mutation detection rate: 10%) and in 115 of 125 bilateral non-familial cases a mutation was identified (mutation detection rate: 92%). Fourteen of the 140 mutations (10%) were shown to be somatic mosaics by regular scanning techniques. Three patients with an RB1 mutation in mosaic state were unilaterally affected (1.2% of non-familial unilateral cases), while eleven had bilateral Rb (8.8% of non-familial bilateral cases). In two bilateral mosaic cases, the mutation was not detected in DNA from blood at first, but after detection of two mutations in tumour DNA it was possible to detect the mosaic mutation in blood DNA. Of 53 unilaterally affected, non-familial Rb patients (21%), tumour DNA was tested for somatic RB1 mutations. The results are listed in table 1. A total of 96 RB1 tumour mutations were detected including 45 small mutations (nonsense (n=29), frameshift (n=11), splice site (n=4), and missense (n=1)) of which 9 were novel mutations (supplementary table 9 ). The remaining mutations were large indels (n=9), promoter hypermethylation (n=8) and LOH (n=34). In three (6%) patients one of the tumour mutations was present in DNA from blood, two of which showed mosaicism. In 46 tumours (87%), two RB1 mutations were found, while in four tumours (7.5%), mutation scanning could detect only one mutation; in one tumour only LOH was detected, another tumour showed only a missense mutation in exon 14 (c.1345G>A /p.Gly449Arg), another only a deletion of RB1 and in the fourth tumour just one nonsense mutation (c.1072C>T /p.Arg358*) in exon 11 was found. In another three tumours (6%), no RB1 mutations could be identified at all. In all these three tumours a high-level amplification of MYCN was detected, as described in our previous study. 
dIScuSSIOn
In this study we describe all RB1 mutations detected in a comprehensive longterm national cohort of 529 Rb patients, 20 non-penetrant mutation carriers and two mutation carriers with retinoma from 433 unrelated families, tested in the Netherlands since 1990. The national health insurance in the Netherlands covers genetic counselling and testing of all relevant genes. Therefore all newly diagnosed Rb patients have been offered DNA testing since the beginning of the 1990s and extensive follow-up procedures have led to the testing of virtually all Rb patients still living from the Dutch National Retinoblastoma Register. 20 Our study cohort thus forms a unique unbiased nationwide group of Rb patients. In our cohort we detected an RB1 mutation in 10% of non-familial unilateral cases. When an RB1 mutation is detected in an Rb patient, the sibs and future children of the patient can be tested for the mutation and appropriate ophthalmological screening from birth can be provided when the mutation is present. In addition, knowledge of the absence of an RB1 mutation in sibs and children can avoid unnecessary and costly eye examinations under anaesthesia. Furthermore, appropriate counselling about reproductive options can be provided to RB1 carriers and parents of children with Rb. As we have shown in previous studies, reproductive behaviour is influenced by Rb for many parents at increased risk for a child with Rb.
8 9 Several patients with Rb in our cohort were unaware of the hereditary nature of their disease and conceived children who developed Rb and were not screened from birth, nor had the parents had the opportunity to consider other reproductive options, e.g. prenatal diagnosis or pre-implantation genetic diagnosis. This stresses the importance to perform RB1 mutation scanning and offer genetic counselling, irrespective of laterality or familial occurrence. The distribution of the different types of mutations is in agreement with most previous studies (Figure 3c) . 15 17 19 24 32 33 In total, 33 out of 187 detected mutations were RB1 mutations not previously described in literature or the LOVD database. 18 Two of the novel mutations were recurrent, the c.862-5T>G mutation was detected as incomplete penetrance mutation in a large family and a nonfamilial patient who had an unaffected parent that also carried the mutation. Although we did not have evidence that these two families were related we cannot rule out the possibility of a common founder. The other novel recurrent mutation (c.1398del) was detected in two unrelated non-familial patients. Furthermore, we have evidence that two RB1 variants, c.42C>T, p.= and c.1966C>T, p.Arg656Trp, previously described as pathogenic 24-26 are more likely to be non-pathogenic variants. We detected two mutations in 46 out of 53 Rb tumours, in four tumours only one mutation was identified, and in three other tumours no mutations could be detected. The latter three tumours were shown to be caused by high-level amplification of MYCN in the absence of mutations in RB1. 31 With the MYCN amplified tumours excluded, we detected 96% (96/100) of expected RB1 mutations in tumours. In the majority of tumours the second hit was LOH (34 / 64%), in line with previous reports.
26 34 35
We have shown several three-generation families with incomplete penetrance for Rb. Most of the families with incomplete penetrance, had splice mutations or missense mutations, confirming other observations described in literature.
15 21
36 37 In three of these families one of the RB1 carriers without Rb had developed a sarcoma that may be RB1-related. In a previous study we have shown that the risk of a second cancer for carriers of a low penetrance RB1 mutation is much lower than for carriers of a mutation with high penetrance. 20 Nevertheless awareness of a possible increased risk is important, and therefore RB1 mutation testing of family members can be useful, even when they will not develop Rb anymore. The detection rate of 92% in familial and/or bilateral cases with the testing scheme we used is similar to detection rates reported by other studies.
15 17 24
Germline mosaicism of the RB1 mutation was found with our current screening protocol in 14 non-familial cases (10% of all non-familial patients with a germline mutation) and in one unaffected parent. Another unaffected parent with multiple bilaterally affected (grand)children may be mosaic, but regular testing did not show mosaicism. In 9.6% of bilaterally affected patients the RB1 mutation was present in a mosaic state, whereas 12% of unilaterally affected patients with a germline RB1 mutation were shown to be mosaic. In the near future we will probably use next generation sequencing as the main diagnostic tool for Rb mutation scanning. Next generation sequencing is expected to increase our mutation detection rate, especially by increasing the detection rate for germline mosaicism. Rushlow et al. increased their mutation detection rate from 92.6% to 94.5% by using allele specific-PCR (AS-PCR) for mosaicism of 11 recurrent RB1 CGA>TGA mutations. 13 A recent study described next generation deep sequencing on blood samples from 20 bilateral and 70 unilateral non-familial Rb patients in whom Sanger sequencing did not detect an RB1 mutation.
38 They detected six low-level mosaic mutations in bilateral Rb and four in unilateral Rb, increasing their detection rate from 96% to 97% for bilateral Rb and from 13% to 18% for unilateral Rb. Since the detection of germline mosaicism has important clinical consequences for the patient and family members as has been pointed out in many papers 26 39 , the ultimate goal remains to detect all RB1 mutations, both in the tumour and the germline. Besides mosaicism, possibilities for a missed mutation in RB1 are deep intronic mutations that create cryptic splice sites 16 or mutations in regulatory regions other than the promoter region we routinely analyse. We therefore analysed RB1 cDNA and performed additional testing of an extended region of the RB1 promoter in several bilateral non-familial and familial Rb patients without detectable RB1 mutations. In mice loss of one of the other Rb pocket proteins, p107 (RBL1) and p130 (RBL2), along with loss of RB1 is required for the development of Rb.
40-43
Although there is currently no evidence for genetic heterogeneity in heritable Rb in humans, we hypothesized that mutations in these other Rb pocket genes might play a role in the development of Rb. However, analysing cDNA of RBL1 and RBL2 in patients without a detectable RB1 mutation did not reveal evidence for mutations in these genes in our Rb patients. Another possibility for a missed mutation is that genes other than RB1, and the other pocket protein genes, might cause Rb in patients where no RB1 mutation can be detected. Several studies describe that polymorphisms in genes in the p53 pathway can modify susceptibility to Rb development.
44-47
In the future, whole genome sequencing could be used to study Rb families or non-familial bilateral Rb patients without detectable RB1 mutations to identify possible mutations or modifying polymorphisms in genes besides RB1. In conclusion, we have shown that sequencing and MLPA are accurate and fast testing methods to detect 92% of RB1 mutations in bilateral and/or familial Rb patients. Distribution of mutation types in our comprehensive national cohort does not differ substantially from the distribution described in most other papers. Further testing for mutations in mosaic state and deep intronic mutations will eventually lead to an even higher mutation detection rate, so more Rb patients and their families can receive accurate risk estimation and use this knowledge for risk management and reproductive decisions.
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RT-PCR was performed with cDNA and 9 primer sets for RB1 (supplementary  table 2 ) and 8 primersets for RBL1 and RBL2 (supplementary tables 3-4) with platinum Taq polymerase (Bioke). Primersets were designed to cover all exons and the corresponding products had a length of approximately 500 bp. PCR products were analyzed on 2% agarose gels. Genomic DNA was extracted from lymphoblastoid cell lines (patients 22, 40, and 244) with the QIAamp DNA blood mini kit (Qiagen) or DNA available from DNA diagnostics was used (patients 185, 224, 2, 130, 140, 210, 242, 288, 306, and 321). The 3226 bp RB1 region containing the promoter, exon 1 and partially intron 1 were PCR amplified sequentially in 7 overlapping fragments of approximately 500 bp (table 5) , with platinum Taq DNA polymerase (Invitrogen) (primer 1-5), because of the high GC content of the regions targeted by primersets 6 and 7, the Accuprime kit (Invitrogen) was used to amplify the latter regions. The PCR was performed with 35 cycli, PCR products were analyzed on 2 % agarose gels.
sequence analysis RB1 promoter and RBL2 trancripts The RT-PCR products of RBL2 and PCR products of the RB1 promoter were used for sequence analysis. PCR fragments were incubated for 30 minutes at 37°C and 15 minutes at 80°C with Shrimp Alkaline Phosphatase (SAP) and Exonuclease I. The cycle-sequencing reaction was performed with BigDye® Terminator v3.1. Cycle Sequencing kit (Applied Biosystems, Bleiswijk, Netherlands). The generated DNAs were subsequently purified with Sephadex G50 Superfine and analyzed with an ABI 3730 DNA analyzer (Applied Biosystems, Bleiswijk, Netherlands). 
